Piper Sandler Companies has announced the addition of Kelsey Goodwin as a director and senior research analyst to their biotechnology equity research team. Goodwin, who will be based in the Boston office, will have coverage responsibilities in oncology. She joins the firm after seven years at Guggenheim, where she focused on oncology, and previously worked in pharmaceutical strategy consulting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.